drugset
Drugs / Tenofovir disoproxyl fumarate
last change Jan 2023 re-read 9 days ago

Tenofovir disoproxyl fumarate

also known as TDF
Developed for
COVID-19 · HIV infectious disease
Investigated by
Bill and Melinda Gates Foundation · CHU de Quebec-Universite Laval · Centre Muraz · Gilead Sciences · Imperial College London · Institut National en Santé Publique du Québec
+5 more · Johns Hopkins University · National AIDS Control Organisation · University of Bristol · University of Montreal · Université d'Abomey-Calavi

Trials 1

today NCT02237027 · Ph 4
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT02237027 Oct 2014 → Dec 2016 — CHU de Quebec-Universite Laval Completed No outcome recorded
Comparator or background therapy2 trials
— NCT04712357 Comparator Nov 2020 → Jan 2022 COVID-19 Federal University of Ceará Unknown No outcome recorded
— NCT01479634 Comparator Oct 2011 → Jun 2015 HIV infectious disease University of California, San Francisco Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Tenofovir disoproxyl fumarate “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗
2

“Combination of Tenofovir disoproxyl fumarate 300mg and Emtricitabine 200 mg” NCT02237027 ↗

NCT04712357 ↗
Known as TDF “fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗
1

“Tenofovir disoproxyl fumarate (TDF; 300 mg / day, for 10 days)” NCT04712357 ↗
Route Oral “one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]” NCT01479634 ↗